Apeiron Investment Group Ltd., 10% Owner, Director at ATAI Life Sciences N.V. (ATAI), bought 17,351,598 shares at $2.19 ($38.0M) on 2025-08-14, disclosed to the SEC on 2025-08-18.
Open-market purchase of $38.0M ATAI by 10% Owner, Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.19 | 8,675,799 | $19.0M | 50.0% |
| 2 | $2.19 | 8,675,799 | $19.0M | 50.0% |
| Total | $2.19 avg | 17,351,598 | $38.0M | 100% |
| Filing → |
| ENHA | BUY | 2026-09-04 | $210K | — | Filing → |
| ENHA | BUY | 2026-08-20 | $2.9M | — | Filing → |
| ENHA | BUY | 2026-08-18 | $330K | — | Filing → |